Description

Send us a text

I’m honored to welcome Randall Feingold, a renowned plastic surgeon and respected member of the American Society of Plastic Surgeons (ASPS), where he also serves on the committee for Breast Implant Illness. Dr. Feingold has been a steadfast voice advocating for women’s health, raising international awareness about the risks of breast implants, the importance of safe and supportive explant recovery, and the urgent need for stronger safety measures and regulations around breast implants. His dedication and expertise continue to inspire and empower women on their healing journeys.

FDA Black-Box Warning for Breast Implants (Example Text Per FDA Guidance)

According to the FDA’s labeling guidance (October 2021) and example from Appendix A, the boxed warning should state:

WARNING:

• Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some of which will require more surgery.
• Breast implants have been associated with the development of a cancer of the immune system called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined. Some patients have died from BIA-ALCL.
• Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.
  U.S. Food and Drug Administration
  facingourrisk.org
  PMC

Why This Matters

1. "Not lifetime devices" underscores that implants often require monitoring, maintenance, or replacement over time—especially relevant for women navigating healing post-explant, where long-term awareness is key.
2. Risk of BIA-ALCL, particularly with textured implants, highlights a serious health concern—knowing this can inform safer decision-making.
3. Systemic symptoms (Breast Implant Illness – BII) such as fatigue, brain fog, autoimmune issues—emphasize that some experiences are physiological and may improve post-explant, aligning closely with your holistic healing approach.

Additional Context and Support for Your Work

• The FDA also requires a Patient Decision Checklist detailing when implants shouldn't be used, risks of surgery, BIA-ALCL, systemic symptoms, and alternatives—reinforced with signatures from both patient and physician
  U.S. Food and Drug Administration+1
  facingourrisk.org.
• Updated guidance includes rupture screening intervals, device material transparency, and patient device cards to improve patient empowerment and tracking
  U.S. Food and Drug Administration

Leoracoca@gmail.com